Big compounders will have until May 22 to stop producing and dispensing compounded semaglutide, while smaller, state-run ...

An estimated 24,499 people visited the ED for adverse events related to semaglutide in the 2 years after its approval for ...

Tirzepatide linked to more GI issues than semaglutide in new study on weight-loss drugs without diabetes. Read more!

Compared with other antidiabetic medications, semaglutide was linked to a significantly lower risk of opioid overdose in ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of its weight loss blockbuster “earlier this year,” according ...

Receiving a generic version of Ozempic or Wegovy from a compounding pharmacy is normally both easier to access and cheaper.

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic neuropathy (NAION).

In May 2023, when Novo reported that patients on the highest dose (50 mg) of oral semaglutide lost 15% of their weight after 64 weeks, the company said it planned to apply for approval by the end ...

Highlights Semaglutide medications like Ozempic may cause facial changes. You can take steps to help minimize or prevent ...